AN EXTENDED RELEASE FORMULATION OF A DIRECT THROMBIN INHIBITOR
Extended release formulations of 3-fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide (DPOC-4088) that provide for better control of blood plasma levels. The extended release formulations maintain substantially constant plasma levels of the active ingre...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
24.09.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Extended release formulations of 3-fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide (DPOC-4088) that provide for better control of blood plasma levels. The extended release formulations maintain substantially constant plasma levels of the active ingredient for at least about 16 hours and provide for once-daily dosing. |
---|---|
Bibliography: | Application Number: EP20120848616 |